Tetanus Clinical Trials

Find Tetanus Clinical Trials Near You

A Randomized, Positive-Controlled Phase I/II Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed in Individuals Aged 2 Months to 6 Years

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

This is a randomized, positive-controlled phase I/II clinical trial to evaluate the safety and preliminary immunogenicity of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed in subjects aged 2 Months to 6 Years.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2 months
Maximum Age: 6
Healthy Volunteers: t
View:

• Age Requirement: volunteers aged 4-6 years, 18-24 months, and 2 months.

• History of preventive inoculation: (1)children aged 4-6 years who have completed immunization with 4 doses of DTP vaccine or another combination vaccine containing DTP antigen components in accordance with the National Immunization Program, and who have not yet received the fifth dose of DTP vaccine; (2)children aged 18-24 months have completed basic immunization with DTP vaccine or another combination vaccine containing DTP antigen components (3 doses) and basic immunization with poliovirus vaccine (3 doses) in accordance with the National Immunization Program, and have not yet received a booster dose of DTP vaccine (the 4th dose) or a booster dose of poliovirus vaccine (the 4th dose); (3) infants aged 2 months have not yet received vaccines containing DTP antigen components, vaccines containing poliovirus antigen components, 13-valent pneumococcal polysaccharide conjugate vaccine, haemophilus influenzae type b conjugate vaccine, or group A and C meningococcal and haemophilustype b conjugate vaccine.

• Provision of Legal Identification: participants and their legal guardians or appointed representatives must provide valid legal identification documents.

• Informed Consent: participants, legal guardians, or appointed representatives of volunteers must have the capacity to understand the informed consent document and the research process, voluntarily participate, sign the informed consent form, and be able to comply with the requirements in the study as well as complete relevant visits on time.

• 2 months old: full term infant (37 weeks ≤ gestational age \< 42 weeks) with a birth weight ≥ 2500 g.

Locations
Other Locations
China
Hechuan District Center for Disease Control and Prevention
RECRUITING
Chongqing
Jiulongpo District Center for Disease Control and Prevention
NOT_YET_RECRUITING
Chongqing
Yongchuan District Center for Disease Control and Prevention
NOT_YET_RECRUITING
Chongqing
Contact Information
Primary
Jingsi Yang
yjs@imbcams.com.cn
0871-68334551
Time Frame
Start Date: 2026-10-11
Estimated Completion Date: 2028-09-25
Participants
Target number of participants: 380
Treatments
Experimental: Experimental Vaccine
Participants aged 2 months to 6 years
Active_comparator: DTacP controlled group
Participants aged 2 months to 6 years
Active_comparator: DTacP+sIPV controlled group
Participants aged 2 to 24 months
Sponsors
Leads: Institute of Medical Biology, Chinese Academy of Medical Sciences

This content was sourced from clinicaltrials.gov